Teleflex Aksje

Teleflex ROE

ROE (Return on Equity) av Teleflex (TFX) per 30. mars 2026 er 0,02.Forrige år var ROE (Return on Equity) 0,08 — en endring på −79,7% (lavere).

ROE

0,02

YoY

−79,7%

Sist oppdatert:

I året 2026 var egenkapitalavkastningen (ROE) til Teleflex 0,02, en økning på −79,7% sammenlignet med 0,08 ROE i forrige år.

Access this data via the Eulerpool API

Teleflex Aksjeanalyse

Hva gjør Teleflex? Teleflex Inc. is a global company founded in 1943. The company is headquartered in Wayne, Pennsylvania, USA and operates in over 40 countries worldwide. It is a leading provider of medical devices, instruments, and accessories for various applications in clinical practice and patient care. The business model of Teleflex is based on the manufacturing and marketing of medical devices and instruments, particularly in the areas of anesthesia, vascular access, interventional medicine, pulmonary and thoracic surgery, urological care, cardiovascular diagnostics, and surgery. The company works closely with medical professionals and clinicians to develop high-quality products that meet the needs of patients and doctors. Teleflex is divided into several business segments, including angiography/diagnostics, anesthesia, oncology, vascular intervention, pulmonology, surgery, and urology. Each of these segments offers a wide range of products and solutions specifically tailored to the needs of doctors and patients. In the angiography/diagnostics segment, Teleflex offers a variety of products that can be used for the diagnosis and treatment of cardiovascular diseases and other medical conditions. These include catheters, guide wires, and sheaths. The anesthesia segment of Teleflex includes products such as ventilation bags, endotracheal tubes, and nebulizer systems. These products are essential for the successful performance of anesthesia procedures and can help doctors save valuable time and resources. The oncology segment of Teleflex offers a wide range of products specifically designed for the treatment of cancer patients. These include catheter-based systems that can facilitate the administration of drugs and other therapies. With the vascular intervention segment, Teleflex offers a comprehensive range of products and solutions specifically designed for the treatment of vascular diseases. These include balloon catheters, stents, and sheaths. The pulmonology segment of Teleflex offers products aimed at facilitating breathing and improving the quality of life for patients with chronic respiratory diseases. These include oxygen concentrators, tracheal tubes, and ventilators. The surgical segment of Teleflex offers a variety of solutions for performing surgical procedures, including surgical instruments, sutures, and wound care materials. The urology segment of Teleflex offers a wide range of products specifically designed for use in urology. These include catheters, wires, and stents. Teleflex is a leading company in the medical technology industry that specializes in the development and marketing of products that improve patients' quality of life and facilitate the work of doctors. With its innovative solutions and a focus on providing the best possible customer service and patient safety, Teleflex has taken on a significant role in the industry and will continue to be an important provider in this market in the future. Teleflex er et av de mest populære selskapene på Eulerpool.

ROE i detalj

Dekoding av egenkapitalavkastningen (ROE) til Teleflex

Egenkapitalavkastningen (ROE) til Teleflex er en grunnleggende nøkkelindikator som vurderer selskapets lønnsomhet i forhold til egenkapitalen. ROE, beregnet ved å dele nettoinntekten med aksjeeiernes egenkapital, illustrerer hvor effektivt selskapet genererer profitt fra aksjonærenes investeringer. En høyere ROE representerer økt effektivitet og profittabilitet.

År-til-år-sammenligning

Analysen av ROE til Teleflex fra år til år bidrar til å følge lønnsomhetstrender og finansiell ytelse. En økende ROE indikerer økt lønnsomhet og verdiskaping for aksjonærene, mens en synkende ROE kan tyde på problemer med å generere profitt eller i styringen av egenkapitalen.

Effekter på investeringer

ROE til Teleflex er avgjørende for investorer som vurderer selskapets lønnsomhet, effektivitet og attraktivitet som investeringsobjekt. En solid ROE indikerer selskapets evne til å omdanne egenkapitalinvesteringer til profitt og øker dermed dets tiltrekningskraft for potensielle og nåværende investorer.

Tolking av svingninger i ROE

Endringer i ROE til Teleflex kan skyldes svingninger i nettoinntekt, egenkapital, eller begge deler. Disse svingningene undersøkes for å vurdere effektiviteten av ledelsen, de finansielle strategiene samt de tilknyttede risikoene og mulighetene, og hjelper investorene med å ta informerte beslutninger.

Ofte stilte spørsmål om Teleflex aksje

ROE (Return on Equity) av Teleflex var 0,08 0,02

Access this data via the Eulerpool API

Lønnsomhet — Teleflex

Alle nøkkeltall — Teleflex